Leukemia

Latest News

The AML Epigenomic Risk model used 946 AML-only peripheral blood or bone marrow samples at diagnosis.
AI Prognostic Tool Confirms Concordance Through Epigenomic Signatures in AML

August 26th 2025

Both experimental models significantly improved upon historical clinical risk trial groups for patients with acute myeloid leukemia.

No minimal residual disease-negativity was observed with tuspetinib in patients with AML, including in a patient with more than 7 months of follow-up data.
Tuspetinib Exhibits Enhanced Efficacy in Diverse Newly Diagnosed AML Group

August 19th 2025

Leading experts gathered in Orlando, FL, to discuss the current and future state of cellular therapy in oncology at the 2025 ICE-T Symposium.
National ICE-T Conference Aims to Make CAR T Safer and More Available

August 2nd 2025

Durable Response to CAR T is Associated With Elevated Activation and Clonotypic Expansion of the Cytotoxic Native T Cell Repertoire
Durable Response to CAR T is Associated With Elevated Activation and Clonotypic Expansion of the Cytotoxic Native T Cell Repertoire

July 30th 2025

Data from the phase 3 BRUIN CLL-314 trial show a progression-free survival trend favoring pirtobrutinib compared with ibrutinib in patients with CLL/SLL.
Pirtobrutinib Yields Noninferior ORR Vs Ibrutinib in CLL/SLL

July 30th 2025

Video Series
Video Interviews
Podcasts
Latest CME Events & Activities

More News